BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human ...
another preclinical study of the drug found that NT-0796 and another NLRP3 inhibitor codenamed NT-0249 were as effective at inducing weight loss in obese mice as Novo Nordisk’s GLP-1 agonist ...
“He brings a wealth of expertise to V Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback